IsoRay

IsoRay Gross Profit

Delisted

The Gross Profit of IsoRay (ISR) as of Nov 5, 2026 is 4.62 M USD. In the previous year, Gross Profit was 5.12 M USD — a change of -9.86% (lower).

Gross Profit

4.62 MUSD

YoY

-9.86%

Last updated:

Gross Profit of IsoRay is 2022 4.62 M USD. Gross Profit of IsoRay was 2021 5.12 M USD. It decreases by -9.86% lower compared to the previous year.

The IsoRay Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2015
167,393.00 USD
Jan 1, 2016
129,154.00 USD
Jan 1, 2017
838,000.00 USD
Jan 1, 2018
1.84 M USD
Jan 1, 2019
3.05 M USD
Jan 1, 2020
5.12 M USD
Jan 1, 2021
5.12 M USD
Jan 1, 2022
4.62 M USD
The IsoRay Gross Profit history
YEARGross ProfitYoY
4.62 MUSD-9.86%
5.12 MUSD-0.06%
5.12 MUSD+68.17%
3.05 MUSD+65.42%
1.84 MUSD+119.81%
838,000.00USD+548.84%
129,154.00USD-22.84%
167,393.00USD-185.20%
-196,471.00USD-230.83%
150,176.00USD-78.64%
703,204.00USD-39.24%
1.16 MUSD+59.47%
725,797.00USD-305.42%
-353,332.00USD+133.32%
-151,434.00USD+177.37%
-54,597.00USD-97.00%
-1.82 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Revenue

IsoRay Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
7.31 M USD
-5.28 M USD
-4.85 M USD
Jan 1, 2020
9.68 M USD
-3.48 M USD
-3.27 M USD
Jan 1, 2021
10.05 M USD
-3.44 M USD
-3.20 M USD
Jan 1, 2022
10.80 M USD
-7.39 M USD
-7.15 M USD
Jan 1, 2023 (e)
16.00 M USD
-7.37 M USD
-7.11 M USD
Jan 1, 2024 (e)
23.96 M USD
6.36 M USD
0.00 USD
Jan 1, 2025 (e)
32.62 M USD
6.14 M USD
5.19 M USD
Jan 1, 2026 (e)
38.51 M USD
5.99 M USD
4.75 M USD

IsoRay Margins

IsoRay stock margins

The IsoRay margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IsoRay. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IsoRay.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
41.66 %
-72.16 %
-66.31 %
Jan 1, 2020
52.93 %
-35.91 %
-33.77 %
Jan 1, 2021
50.94 %
-34.19 %
-31.80 %
Jan 1, 2022
42.76 %
-68.47 %
-66.26 %
Jan 1, 2023 (e)
42.76 %
-46.09 %
-44.41 %
Jan 1, 2024 (e)
42.76 %
26.55 %
0.00 %
Jan 1, 2025 (e)
42.76 %
18.83 %
15.92 %
Jan 1, 2026 (e)
42.76 %
15.56 %
12.32 %

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IsoRay stock

Gross Profit of IsoRay is 4.62 M USD in 2022.

Gross Profit of IsoRay changed from 5.12 M USD to 4.62 M USD, representing a -9.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit IsoRay since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's IsoRay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — IsoRay

All Key Metrics — IsoRay